Finance

The Resilience Of The US Economy

It is crystal clear that the US economy is one of the strongest in the world. Economically speaking, it is far ahead of Europe and Asia and everything points in the direction of the fact that this will continue to be the case for the foreseeable future. The US central bank’s response to the arrival…

EC Russia, Oil

As the year winds down, a Gordian knot tying Russia, oil prices and China together is receiving a great deal of attention.  Let’s see if we can unravel some of the confusing twists and turns.   We turn first to China’s offer of assistance to Russia.  The idea that Russia could activate its CNY150 bln (~$24 bln) currency…

“Speculators” Drive Oil Price Lower

Usually, gamblers make their money when speculating on commodity prices by betting that the value will rise, allowing them to sell their holdings at a profit. Whilst it is entirely possible to make a killing by shorting the market, usually it is done on the share markets rather than on commodities. However, according to a…

E

Since 2010, our top scoring weekly has outpaced the SPX by a median 328 bps in the following year. The best performers from our list one year ago are AGN up 96%, MAR up 61%, GD up 52%, and SIAL up 49%. Healthcare is the top scoring large cap sector. The best scoring large cap…

Morning Call For December 23, 2014

OVERNIGHT MARKETS AND NEWS March E-mini S&Ps (ESH15 +0.10%) this morning are up +0.11% and European stocks are up +0.40% on expectations that U.S. Q3 GDP will be revised upward and Nov durable goods orders will show a solid gain. Asian stocks closed mixed: Japan closed for holiday, Hong Kong -0.32%, China -2.05%, Taiwan +0.03%, Australia -1.12%, Singapore +0.05%,…

Housing’s Wobbly But The Economy’s Strong… Huh?

US economic growth accelerated last month, according to the November update of the Chicago Fed National Activity Index. But while the broad trend is looking stronger these days, housing remains wobbly. Existing home sales fell a hefty 6.1% in November – the biggest monthly decline in over four years. The slide follows last week’s news of November’s sluggish growth in housing…

CERS Reports US Phase 2 Clinical Trial Of INTERCEPT Met Primary E

Cerus Corporation (NASDAQ: CERS) announced its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated red blood cells continued to circulate 24 hours following transfusion. The investigators plan to submit data from the study for presentation…